Overexpression of X-Box binding protein 1 (XBP1) correlates to poor prognosis and up-regulation of PI3K/mTOR in human osteosarcoma

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28635-28646

  Yang, Jielai ^a   Cheng, Dongdong ^a   Zhou, Shumin ^a   Zhu, Bin ^a   Hu, Tu ^a   Yang, Qingcheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Growth; Osteosarcoma; PI3K mTOR signaling; Survival; X box binding protein 1

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; X BOX BINDING PROTEIN 1; DNA BINDING PROTEIN; PIK3R3 PROTEIN, HUMAN; REGULATORY FACTOR X TRANSCRIPTION FACTOR; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR; XBP1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; OSTEOSARCOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; WESTERN BLOTTING; ADOLESCENT; ADULT; BONE TUMOR; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; CELL HYPOXIA; DISEASE COURSE; FEMALE; GENETICS; MALE; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; YOUNG ADULT;

ADOLESCENT; ADULT; BONE NEOPLASMS; CASE-CONTROL STUDIES; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; REGULATORY FACTOR X TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR BURDEN; UP-REGULATION; X-BOX BINDING PROTEIN 1; YOUNG ADULT;

EID: 84949457826     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226123     Document Type: Article

References (44)

1. Ando, K.; Heymann, M.F.; Stresing, V.; Mori, K.; Rédini, F.; Heymann, D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers 2013, 5, 591–616. [CrossRef] [PubMed]
2. Raymond, A.K.; Jaffe, N. Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective. Pediatr. Adolesc. Osteosarcoma 2009, 152, 63–84.
3. Luetke, A.; Meyers, P.A.; Lewis, I.; Juergens, H. Osteosarcoma treatment–where do we stand? A state of the art review. Cancer Treat. Rev. 2014, 40, 523–532. [CrossRef] [PubMed]
4. O'Day, K.; Gorlick, R. Novel therapeutic agents for osteosarcoma. Expert Rev. Anticancer Ther. 2009, 9, 511–523. [CrossRef] [PubMed]
5. Allison, D.C.; Carney, S.C.; Ahlmann, E.R.; Hendifar, A.; Chawla, S.; Fedenko, A.; Angeles, C.; Menendez, L.R. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 2012, 704872. [CrossRef] [PubMed]
6. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
7. Uemura, A.; Oku, M.; Mori, K.; Yoshida, H. Unconventional splicing of XBP1 mRNA occurs in the cytoplasm during the mammalian unfolded protein response. J. Cell Sci. 2009, 122, 2877–2886. [CrossRef] [PubMed]
8. Lee, K.; Tirasophon, W.; Shen, X.; Michalak, M.; Prywes, R.; Okada, T.; Yoshida, H.; Mori, K.; Kaufman, R.J. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev. 2002, 16, 452–466. [CrossRef] [PubMed]
9. Yoshida, H. ER stress and diseases. FEBS J. 2007, 274, 630–658. [CrossRef] [PubMed]
10. Fang, D.L.; Wan, Y.; Shen, W.; Cao, J.; Sun, Z.X.; Yu, H.H.; Zhang, Q.; Cheng, W.H.; Chen, J.; Ning, B. Endoplasmic reticulum stress leads to lipid accumulation through upregulation of SREBP-1c in normal hepatic and hepatoma cells. Mol. Cell. Biochem. 2013, 381, 127–137. [CrossRef] [PubMed]
11. Ning, J.; Hong, T.; Ward, A.; Pi, J.; Liu, Z.; Liu, H.-Y.; Cao, W. Constitutive role for IRE1 -XBP1 signaling pathway in the insulin-mediated hepatic lipogenic program. Endocrinology 2011, 152, 2247–2255. [CrossRef] [PubMed]
12. Sha, H.; He, Y.; Chen, H.; Wang, C.; Zenno, A.; Shi, H.; Yang, X.; Zhang, X.; Qi, L. The IRE1 -XBP1 pathway of the unfolded protein response is required for adipogenesis. Cell Metab. 2009, 9, 556–564. [CrossRef] [PubMed]
13. Martinet, W.; Croons, V.; Timmermans, J.P.; de Meyer, G. Nitric oxide selectively depletes macrophages in atherosclerotic plaques via induction of endoplasmic reticulum stress. Br. J. Pharmacol. 2007, 152, 493–500. [CrossRef] [PubMed]
14. Zeng, L.; Zampetaki, A.; Margariti, A.; Pepe, A.E.; Alam, S.; Martin, D.; Xiao, Q.; Wang, W.; Jin, Z.-G.; Cockerill, G., et al. Sustained activation of XBP1 splicing leads to endothelial apoptosis and atherosclerosis development in response to disturbed flow. Proc. Natl. Acad. Sci. USA 2009, 106, 8326–8331. [CrossRef] [PubMed]
15. Breckenridge, D.G.; Germain, M.; Mathai, J.P.; Nguyen, M.; Shore, G.C. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 2003, 22, 8608–8618. [CrossRef] [PubMed]
16. Romero-Ramirez, L.; Cao, H.; Nelson, D.; Hammond, E.; Lee, A.-H.; Yoshida, H.; Mori, K.; Glimcher, L.H.; Denko, N.C.; Giaccia, A.J., et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 2004, 64, 5943–5947.
17. Xu, G.; Liu, K.; Anderson, J.; Patrene, K.; Lentzsch, S.; Roodman, G.D.; Ouyang, H. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood 2012, 119, 4205–4214. [CrossRef] [PubMed]
18. Chen, X.; Iliopoulos, D.; Zhang, Q.; Tang, Q.; Greenblatt, M.B.; Hatziapostolou, M.; Lim, E.; Tam, W.L.; Ni, M.; Chen, Y., et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 2014, 508, 103–107. [CrossRef] [PubMed]
19. Gambella, M.; Rocci, A.; Passera, R.; Gay, F.; Omedè, P.; Crippa, C.; Corradini, P.; Romano, A.; Rossi, D.; Ladetto, M., et al. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica 2014, 99, 14–16. [CrossRef] [PubMed]
20. Vincenz, L.; Jager, R.; O'Dwyer, M.; Samali, A. Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma. Mol. Cancer Ther. 2013, 12, 831–843. [CrossRef] [PubMed]
21. Martin, D.; Li, Y.; Yang, J.; Wang, G.; Margariti, A.; Jiang, Z.; Yu, H.; Zampetaki, A.; Hu, Y.; Xu, Q., et al. Unspliced X-box-binding protein 1 (XBP1) protects endothelial cells from oxidative stress through interaction with histone deacetylase 3. J. Biol. Chem. 2014, 289, 30625–30634. [CrossRef] [PubMed]
22. Zeng, L.; Xiao, Q.; Chen, M.; Margariti, A.; Martin, D.; Ivetic, A.; Xu, H.; Mason, J.; Wang, W.; Cockerill, G., et al. Vascular endothelial cell growth-activated XBP1 splicing in endothelial cells is crucial for angiogenesis. Circulation 2013, 127, 1712–1722. [CrossRef] [PubMed]
23. Clarke, H.J.; Chambers, J.E.; Liniker, E.; Marciniak, S.J. Endoplasmic reticulum stress in malignancy. Cancer Cell 2014, 25, 563–573. [CrossRef] [PubMed]
24. Koumenis, C. ER stress, hypoxia tolerance and tumor progression. Curr. Mol. Med. 2006, 6, 55–69. [CrossRef] [PubMed]
25. Shajahan, A.N.; Riggins, R.B.; Clarke, R. The role of X-box binding protein-1 in tumorigenicity. Drug News Perspect. 2009, 22, 241–246. [CrossRef] [PubMed]
26. Davies, M.P.; Barraclough, D.L.; Stewart, C.; Joyce, K.A.; Eccles, R.M.; Barraclough, R.; Rudland, P.S.; Sibson, D.R. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int. J. Cancer 2008, 123, 85–88. [CrossRef] [PubMed]
27. Romero-Ramirez, L.; Cao, H.; Regalado, M.P.; Kambham, N.; Siemann, D.; Kim, J.J.; Le, Q.T.; Koong, A.C. X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. Transl. Oncol. 2009, 2, 31–38. [CrossRef] [PubMed]
28. Nakamura, M.; Gotoh, T.; Okuno, Y.; Tatetsua, H.; Sonokia, T.; Unedaa, S.; Morib, M.; Mitsuyaa, H.; Hata, H. Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells. Leuk. Lymphoma 2006, 47, 531–539. [CrossRef] [PubMed]
29. Papandreou, I.; Denko, N.C.; Olson, M.; van Melckebeke, H.; Lust, S.; Tam, A.; Solow-Cordero, D.E.; Bouley, D.M.; Offner, F.; Niwa, M., et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011, 117, 1311–1314. [CrossRef] [PubMed]
30. Mimura, N.; Fulciniti, M.; Gorgun, G.; Tai, Y.-T.; Cirstea, D.; Santo, L.; Hu, Y.; Fabre, C.; Minami, J.; Ohguchi, H., et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 2012, 119, 5772–5781. [CrossRef] [PubMed]
31. Carrasco, D.R.; Sukhdeo, K.; Protopopova, M.; Sinha, R.; Enos, M.; Carrasco, D.E.; Zheng, M.; Mani, M.; Henderson, J.; Pinkus, G.S., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11, 349–360. [CrossRef] [PubMed]
32. Leung-Hagesteijn, C.; Erdmann, N.; Cheung, G.; Keats, J.J.; Stewart, A.K.; Reece, D.E.; Chung, K.C.; Tiedemann, R.E. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013, 24, 289–304. [CrossRef] [PubMed]
33. Hetz, C.; Martinon, F.; Rodriguez, D.; Glimcher, L.H. The unfolded protein response: Integrating stress signals through the stress sensor IRE1. Physiol. Rev. 2011, 91, 1219–1243. [CrossRef] [PubMed]
34. Kim, R.; Emi, M.; Tanabe, K.; Murakami, S. Role of the unfolded protein response in cell death. Apoptosis 2006, 11, 5–13. [CrossRef] [PubMed]
35. Oyadomari, S.; Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004, 11, 381–389. [CrossRef] [PubMed]
36. Auf, G.; Jabouille, A.; Guerit, S.; Pineau, R.; Delugin, M.; Bouchecareilh, M.; Magnin, N.; Favereaux, A.; Maitref, M.; Gaiser, T., et al. Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc. Natl. Acad. Sci. USA 2010, 107, 15553–15558. [CrossRef] [PubMed]
37. Fujimoto, T.; Yoshimatsu, K.; Watanabe, K.; Yokomizo, H.; Otani, T.; Matsumoto, A.; Osawa, G.; Onda, M.; Ogawa, K. Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas. Anticancer Res. 2007, 27, 127–131. [PubMed]
38. Niederreiter, L.; Fritz, T.M.; Adolph, T.E.; Krismer, A.M.; Offner, F.A.; Tschurtschenthaler, M.; Flak, M.B.; Hosomi, S.; Tomczak, M.F.; Kaneider, N.C., et al. ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells. J. Exp. Med. 2013, 210, 2041–2056. [CrossRef] [PubMed]
39. Koong, A.C.; Chauhan, V.; Romero-Ramirez, L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol. Ther. 2006, 5, 756–759. [CrossRef] [PubMed]
40. Jiang, D.; Niwa, M.; Koong, A.C. Targeting the IRE1 -XBP1 branch of the unfolded protein response in human diseases. Semin. Cancer Biol. 2015, 33, 48–56. [CrossRef] [PubMed]
41. Chen, S.; Sang, N. Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells. J. Cell. Biochem. 2015. [CrossRef] [PubMed]
42. Chen, S.; Yin, C.; Lao, T.; Lianga, D.; Hea, D.; Wang, C.; Sanga, N. AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1alpha and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol. Cell Cycle 2015, 14, 2520–2536. [CrossRef] [PubMed]
43. Mizukami, Y.; Kohgo, Y.; Chung, D.C. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin. Cancer Res. 2007, 13, 5670–5674. [CrossRef] [PubMed]
44. Porta, C.; Paglino, C.; Mosca, A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front. Oncol. 2014, 4, 64. [CrossRef] [PubMed]